We advised PegBio on its IPO and HKEX listing

Davis Polk advised PegBio Co., Ltd. in connection with its initial public offering and listing on the Hong Kong Stock Exchange and its international offering pursuant to Regulation S.

PegBio is a biotechnology company focused on the in-house discovery and development of innovative therapies – primarily peptide and small molecule drugs – for chronic diseases, with a particular emphasis on metabolic disorders.

The Davis Polk corporate team included partners Li He, Xuelin (Steve) Wang and Jason Xu, counsel – registered foreign lawyer Jennifer (Yujia) Jiang, counsel Wendy Kan and associates Michelle Chow and Jamie Lai. Members of the Davis Polk team are based in the Hong Kong and Beijing offices.

Copy link to share post